Cardlytics (CDLX) Panoramica del titolo
Cardlytics, Inc. gestisce una piattaforma pubblicitaria negli Stati Uniti e nel Regno Unito. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 3/6 |
| Crescita futura | 0/6 |
| Prestazioni passate | 0/6 |
| Salute finanziaria | 2/6 |
| Dividendi | 0/6 |
Premi
Analisi del rischio
CDLX Community Fair Values
Create NarrativeSee what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Concorrenti di Cardlytics, Inc.
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | US$4.71 |
| Massimo di 52 settimane | US$32.80 |
| Minimo di 52 settimane | US$4.50 |
| Beta | 0.58 |
| Variazione di 1 mese | -33.99% |
| Variazione a 3 mesi | -49.48% |
| Variazione di 1 anno | -70.38% |
| Variazione a 3 anni | -92.55% |
| Variazione a 5 anni | -99.62% |
| Variazione dall'IPO | -96.48% |
Notizie e aggiornamenti recenti
Aggiornamento della narrazione • Jun 16
CDLX: Reverse Split And Margin Outlook Will Drive Future Repricing
Analysts have raised their fair value estimate for Cardlytics to $10.75 from $1.08, citing updated price target work that incorporates unchanged discount rate assumptions, a slightly higher long term profit margin outlook, and a modestly lower future P/E multiple. What’s in the News for Cardlytics Cardlytics plans a 1 for 10 reverse stock split of its common stock, with the company’s shares expected to begin trading on a split adjusted basis on The Nasdaq Global Market on June 8, 2026, and the new CUSIP number set as 14161W303.Aggiornamento della narrazione • Jun 02
CDLX: Reset Expectations And Partner Exit Will Drive Future Repricing
Analysts have edged Cardlytics' fair value estimate up to about $1.08 per share, while tightening assumptions around discount rate, revenue contraction, profit margins and future P/E. This reflects recent price target cuts to $1 to $1.25 that they see as better aligned with updated guidance and the impact of the BofA exit and Bridg sale.
Aggiornamento della narrazione • May 15
CDLX: Reset Guidance And Banking Shifts Will Drive Future Repricing Potential
Narrative update on Cardlytics The analyst price target for Cardlytics has shifted from $1.25 to $1.50, with analysts pointing to updated assumptions around discount rates, revenue trends, margins, and future P/E after recent resets in expectations following Q4 results, Q1 guidance, and the impact of the BofA exit and Bridg divestiture. Analyst Commentary Recent research has centered on how Cardlytics should be valued after its Q4 results, Q1 guidance, and the announced BofA exit and Bridg divestiture.Recent updates
Aggiornamento della narrazione • Jun 16
CDLX: Reverse Split And Margin Outlook Will Drive Future Repricing
Analysts have raised their fair value estimate for Cardlytics to $10.75 from $1.08, citing updated price target work that incorporates unchanged discount rate assumptions, a slightly higher long term profit margin outlook, and a modestly lower future P/E multiple. What’s in the News for Cardlytics Cardlytics plans a 1 for 10 reverse stock split of its common stock, with the company’s shares expected to begin trading on a split adjusted basis on The Nasdaq Global Market on June 8, 2026, and the new CUSIP number set as 14161W303.Aggiornamento della narrazione • Jun 02
CDLX: Reset Expectations And Partner Exit Will Drive Future Repricing
Analysts have edged Cardlytics' fair value estimate up to about $1.08 per share, while tightening assumptions around discount rate, revenue contraction, profit margins and future P/E. This reflects recent price target cuts to $1 to $1.25 that they see as better aligned with updated guidance and the impact of the BofA exit and Bridg sale.Aggiornamento della narrazione • May 15
CDLX: Reset Guidance And Banking Shifts Will Drive Future Repricing Potential
Narrative update on Cardlytics The analyst price target for Cardlytics has shifted from $1.25 to $1.50, with analysts pointing to updated assumptions around discount rates, revenue trends, margins, and future P/E after recent resets in expectations following Q4 results, Q1 guidance, and the impact of the BofA exit and Bridg divestiture. Analyst Commentary Recent research has centered on how Cardlytics should be valued after its Q4 results, Q1 guidance, and the announced BofA exit and Bridg divestiture.Articolo di analisi • May 11
Cardlytics, Inc. (NASDAQ:CDLX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
Cardlytics, Inc. ( NASDAQ:CDLX ) just released its latest first-quarter results and things are looking bullish...Aggiornamento della narrazione • May 01
CDLX: Reset Expectations And Banking Partner Shifts Will Drive Future Repricing
Analysts have nudged Cardlytics' average price target lower to about $1, with cuts from $2 to $1 and from $1.50 to $1.25. These changes reflect updated views after Q4 results, Q1 guidance, and the expected impact of the BofA exit and Bridg divestiture.Aggiornamento della narrazione • Apr 17
CDLX: Reset Guidance And BofA Exit Will Drive Upside Potential
Narrative Update on Cardlytics Analysts have cut their Cardlytics price targets to a range of about $1 to $1.25, citing Q1 guidance that resets expectations following the Bank of America exit and Bridg divestiture and leaves the stock in what they describe as "show me" territory. Analyst Commentary Recent research updates underline that Q1 guidance and the effects of the Bank of America exit and Bridg divestiture are central to how analysts are framing Cardlytics today.Aggiornamento della narrazione • Apr 03
CDLX: Reset Expectations And Partner Changes Will Shape Future Repricing
Analysts have trimmed Cardlytics' implied fair value from about $1.29 to roughly $1.04. This reflects recent price target cuts to $1 and $1.25 as they factor in softer revenue expectations and the impact of the BofA exit and Bridg divestiture.Aggiornamento della narrazione • Mar 20
CDLX: Reset Guidance And One Bank Exit Will Define Upside Potential
Narrative update on Cardlytics Analysts have trimmed Cardlytics' implied fair value from about $2.00 to roughly $1.25, reflecting lower price targets around $1.00 to $1.25 after Q1 guidance reset expectations for revenue trends, margins and future P/E as the business adjusts to the BofA exit and Bridg divestiture. Analyst Commentary Recent Street research has centered on recalibrated price targets around Q1 guidance and the operational impact of the BofA exit and Bridg divestiture.Aggiornamento della narrazione • Mar 06
CDLX: Reset Expectations And CFO Return Will Support Future Rerating
Analysts have trimmed their Cardlytics price target from $1.50 to $1.25, reflecting updated assumptions around fair value, revenue trends, and profitability following recent guidance resets and business changes. Analyst Commentary Recent commentary around the reduced US$1.25 price target centers on how quickly Cardlytics can adjust to its updated outlook and business mix after the Q1 guidance reset, the BofA exit, and the Bridg divestiture.Articolo di analisi • Jan 08
Cardlytics, Inc. (NASDAQ:CDLX) Stock Catapults 30% Though Its Price And Business Still Lag The Industry
Those holding Cardlytics, Inc. ( NASDAQ:CDLX ) shares would be relieved that the share price has rebounded 30% in the...Seeking Alpha • Oct 06
Cardlytics: Debt Overhang Casts Shadow On Upside
Summary Cardlytics is dealing with a significant headwind in Q3 due to restrictions from its largest bank partner. CDLX sold off sharply following Q2 results, but has since rallied following a bullish report from Citron Research. Management is targeting positive FCF through growth with its newest large bank partner while also substantially lowering operating expenses. Debt remains the biggest risk, though the earliest maturity is not until April 2028. I remain cautious until I see evidence of sequential growth and improving cash burn. Read the full article on Seeking AlphaAggiornamento della narrazione • Aug 08
Bank Partnerships And Data-Driven Marketing Will Shape Future Markets
The notable downward revision in Cardlytics’ price target reflects sharply reduced revenue growth forecasts and a higher discount rate, resulting in a new consensus fair value of $2.10. What's in the News Cardlytics provided Q3 2025 revenue guidance of $52.2 million to $58.2 million.Articolo di analisi • Jul 23
Revenues Tell The Story For Cardlytics, Inc. (NASDAQ:CDLX) As Its Stock Soars 64%
Cardlytics, Inc. ( NASDAQ:CDLX ) shares have continued their recent momentum with a 64% gain in the last month alone...Articolo di analisi • Jul 05
Is Cardlytics (NASDAQ:CDLX) Using Debt Sensibly?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Articolo di analisi • May 29
Cardlytics, Inc. (NASDAQ:CDLX) Soars 30% But It's A Story Of Risk Vs Reward
Cardlytics, Inc. ( NASDAQ:CDLX ) shareholders are no doubt pleased to see that the share price has bounced 30% in the...Articolo di analisi • Apr 07
Why Investors Shouldn't Be Surprised By Cardlytics, Inc.'s (NASDAQ:CDLX) 30% Share Price Plunge
Unfortunately for some shareholders, the Cardlytics, Inc. ( NASDAQ:CDLX ) share price has dived 30% in the last thirty...
Nuova narrazione • Apr 03
US Neobank And Taiwan Office Will Unlock New Markets
Expansion into new sectors and partnerships with financial institutions and neobanks is expected to diversify the customer base and boost revenue.Articolo di analisi • Mar 11
Cardlytics (NASDAQ:CDLX) Has Debt But No Earnings; Should You Worry?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Articolo di analisi • Feb 21
Revenues Tell The Story For Cardlytics, Inc. (NASDAQ:CDLX)
It's not a stretch to say that Cardlytics, Inc.'s ( NASDAQ:CDLX ) price-to-sales (or "P/S") ratio of 0.5x right now...Seeking Alpha • Feb 13
Cardlytics: Short-Term Headwinds Drive Long-Term Success
Summary Cardlytics, Inc. offers an asymmetric investment opportunity for those who can handle stock price volatility and slow business progress. Recent issues with ad deliveries have impacted revenue and market sentiment but positioned the company for long-term success. The shift to engagement-based pricing is expected to drive broader platform adoption. Trading at just 0.51x P/S and 1.10x EV/Revenue, Cardlytics presents significant upside potential from current valuations. Amex Partnership could add $600 million in market value based on $35 million in incremental EBITDA for 2025. Read the full article on Seeking AlphaArticolo di analisi • Jan 10
At US$3.35, Is It Time To Put Cardlytics, Inc. (NASDAQ:CDLX) On Your Watch List?
Cardlytics, Inc. ( NASDAQ:CDLX ), might not be a large cap stock, but it saw significant share price movement during...Seeking Alpha • Dec 07
Cardlytics Continues Revenue Contraction Amid Worsening Economics
Summary Cardlytics, Inc. beat revenue and earnings estimates, but faces declining unit economics and revenue stabilization challenges. The AdTech market is projected to grow significantly, yet CDLX struggles with delivery inefficiencies, declining ARPU, and advertiser hesitancy, impacting its financial performance. Recent financial trends show falling revenue, negative operating income, and high stock-based compensation, with significant cash burn and a 52.1% stock price decline over the past year. Management's turnaround efforts may take several quarters, with increased R&D spending expected to further negatively affect operating results. My outlook on CDLX is to sell. Read the full article on Seeking AlphaArticolo di analisi • Nov 23
Estimating The Intrinsic Value Of Cardlytics, Inc. (NASDAQ:CDLX)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Cardlytics fair value estimate is US$3.50 Current share price...Articolo di analisi • Nov 05
After Leaping 27% Cardlytics, Inc. (NASDAQ:CDLX) Shares Are Not Flying Under The Radar
Cardlytics, Inc. ( NASDAQ:CDLX ) shareholders are no doubt pleased to see that the share price has bounced 27% in the...Articolo di analisi • Oct 15
Is Cardlytics (NASDAQ:CDLX) Using Too Much Debt?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Seeking Alpha • Sep 17
Cardlytics: Execution Risks Are Elevated, But Reasons For Optimism Remain (Maintain Hold Rating)
Summary Shares have fallen nearly 50% since the Q2 earnings report, which came in well below management’s guidance. With Q3 guidance pointing to further weakness, the company’s financial health hinges on management’s execution towards solving the ongoing issues on its ads platform. Assuming no additional setbacks, the company should return to growth next year and generate positive FCF. While risks remain high, the current valuation is undemanding, leading me to maintain a Neutral rating. Read the full article on Seeking AlphaArticolo di analisi • Aug 09
Cardlytics, Inc.'s (NASDAQ:CDLX) 63% Share Price Plunge Could Signal Some Risk
Cardlytics, Inc. ( NASDAQ:CDLX ) shareholders that were waiting for something to happen have been dealt a blow with a...Seeking Alpha • Jul 02
Cardlytics: Has Multiple Potential Growth Levers, But Persistent Risks Remain
Summary Cardlytics shares have declined significantly after Q1 earnings came in below management’s guidance. Key metrics show that the business is performing well. Recent steps taken by management have extended its debt until 2029, leaving the company in a more stable financial position. CDLX has multiple growth levers and significant risks that investors should consider. Read the full article on Seeking AlphaArticolo di analisi • May 31
Cardlytics, Inc.'s (NASDAQ:CDLX) Stock Retreats 30% But Revenues Haven't Escaped The Attention Of Investors
The Cardlytics, Inc. ( NASDAQ:CDLX ) share price has softened a substantial 30% over the previous 30 days, handing back...Seeking Alpha • Apr 17
The Power Of Cardlytics' Data Partnerships Including Bank of America
Summary Cardlytics recently appointed Liane Hornsey to its Board of Directors, which could attract new investors and accelerate hiring and productivity. The company offers a suite of solutions for advertising, marketing, and customer engagement through its own mobile application and partnerships with financial institutions. Future growth projects, synergies, database integration, and new partnerships have the potential to drive net sales growth and increase investor attention. Read the full article on Seeking AlphaArticolo di analisi • Apr 10
Cardlytics, Inc.'s (NASDAQ:CDLX) 81% Jump Shows Its Popularity With Investors
Despite an already strong run, Cardlytics, Inc. ( NASDAQ:CDLX ) shares have been powering on, with a gain of 81% in the...Seeking Alpha • Feb 16
Cardlytics: Good Prospects But Macro Uncertain
Summary Cardlytics has access to 50% of card swipe data through its relationships with major US consumer banks. The company's acquisitions of Dosh and Bridg have strengthened and diversified its platform. The impact of macroeconomic factors on consumer spending and advertising budgets may constrain Cardlytics' growth in the short to medium term. Read the full article on Seeking AlphaArticolo di analisi • Jan 18
Cardlytics, Inc.'s (NASDAQ:CDLX) 29% Share Price Plunge Could Signal Some Risk
Unfortunately for some shareholders, the Cardlytics, Inc. ( NASDAQ:CDLX ) share price has dived 29% in the last thirty...Articolo di analisi • Jan 04
Would Cardlytics (NASDAQ:CDLX) Be Better Off With Less Debt?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Rendimenti per gli azionisti
| CDLX | US Media | US Mercato | |
|---|---|---|---|
| 7D | -9.4% | -1.2% | -2.6% |
| 1Y | -70.4% | -23.9% | 20.0% |
Ritorno vs Industria: CDLX ha avuto una performance inferiore rispetto al US Media che ha registrato un rendimento -23.9 % nell'ultimo anno.
Rendimento vs Mercato: CDLX ha avuto una performance inferiore al mercato US che ha registrato un rendimento 20 % nell'ultimo anno.
Volatilità dei prezzi
| CDLX volatility | |
|---|---|
| CDLX Average Weekly Movement | 14.0% |
| Media Industry Average Movement | 8.8% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
Prezzo delle azioni stabile: Negli ultimi 3 mesi il prezzo delle azioni di CDLX è stato volatile rispetto al mercato US.
Volatilità nel tempo: La volatilità settimanale di CDLX è diminuita da 21% a 14% nell'ultimo anno, ma è comunque superiore al 75% delle azioni US.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 2008 | 224 | Amit Gupta | www.cardlytics.com |
Cardlytics, Inc. gestisce una piattaforma pubblicitaria negli Stati Uniti e nel Regno Unito. L'azienda fornisce la piattaforma Cardlytics, un canale pubblicitario proprietario nativo per le banche che consente agli operatori del marketing di raggiungere i clienti attraverso i canali digitali, come l'online, le applicazioni mobili, le e-mail e varie notifiche in tempo reale; e la piattaforma Bridg, una piattaforma di dati sui clienti che utilizza i dati dei punti vendita dei partner commerciali, compresi i dati di acquisto a livello di prodotto, per consentire agli operatori del marketing di effettuare analisi e marketing di fidelizzazione mirato, nonché di misurare l'impatto del loro marketing. Cardlytics, Inc. è stata costituita nel 2008 e ha sede ad Atlanta, in Georgia.
Cardlytics, Inc. Riepilogo dei fondamenti
| CDLX statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | US$28.63m |
| Utili (TTM) | -US$106.97m |
| Ricavi(TTM) | US$211.16m |
0.1x
Rapporto P/S-0.3x
Rapporto P/ECDLX è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| CDLX Conto economico (TTM) | |
|---|---|
| Ricavi | US$211.16m |
| Costo del fatturato | US$110.95m |
| Profitto lordo | US$100.21m |
| Altre spese | US$207.18m |
| Utili | -US$106.97m |
Ultimi utili riportati
Mar 31, 2026
Prossima data di guadagno
n/a
| Utile per azione (EPS) | -18.57 |
| Margine lordo | 47.46% |
| Margine di profitto netto | -50.66% |
| Rapporto debito/patrimonio netto | -5,101.2% |
Come si è comportato CDLX nel lungo periodo?
Vedi performance storica e confrontoAnalisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/06/26 13:58 |
| Prezzo dell'azione a fine giornata | 2026/06/26 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; disponiamo inoltre di guide su come utilizzare i nostri report e di tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Cardlytics, Inc. è coperta da 12 analisti. 4 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Omar Dessouky | BofA Global Research |
| Jason Kreyer | Craig-Hallum Capital Group LLC |
| Robert Coolbrith | Evercore ISI |